Abstract
All licensed COVID-19 antibody treatments become ineffective over time as new mutants emerge. We isolated antibodies from an individual who recovered from SARS-1 and received the COVID vaccine, that work against all COVID-related viruses including the latest Omicron variants. These broad-targeting antibodies could make future-proof therapeutics to counter the continual evolution of coronaviruses.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
